CellCept, Mycophenolate

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 38 in CellCept, Mycophenolate (generic)

  1. Can EBV Cause Severe Diarrhea; polyDNA Answers This Survey Question...Read the original story

    Friday Apr 11 | PRWeb

    In its March 2014 survey, polyDNA found that 89% of respondents did not know that the Epstein Barr Virus can cause inflammation throughout the rectum and colon, which in turn can lead to severe diarrhea.

    Comment?

  2. Kidney involvement in autoimmune...Read the original story

    Wednesday Apr 9 | CiteULike

    Autoimmune tubulo-interstitial nephritis is a rare complication of autoimmune dystrophy .

    Comment?

  3. Characteristics of Patients with Mild to Moderate Primary Pulmonary CoccidioidomycosisRead the original story w/Photo

    Monday Apr 7 | Centers for Disease Control and Prevention

    To determine the evolution of symptoms and changes in laboratory values for patients with mild to moderate coccidioidomycosis during 2010-2012, we conducted a prospective 24-week study of patients with primary pulmonary coccidioidomycosis.

    Comment?

  4. Findings from University of Ulsan Provide New Insights into HematopoieticRead the original story

    Wednesday Mar 19 | Hispanic Business

    We performed re-transplantation using haploidentical-related donors to rescue children with early GF."

    Comment?

  5. Paid Lupus Clinical Trial Now Enrolling at Achieve Clinical Research...Read the original story

    Mar 12, 2014 | 24-7 Press Release

    Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus .

    Comment?

  6. Paid Lupus Clinical Trial Now Enrolling at Achieve Clinical Research...Read the original story

    Mar 11, 2014 | PRWeb

    Paid Lupus Clinical Trial Now Enrolling at Achieve Clinical Research Near Birmingham, Alabama; Accepting M/F Patients With Lupus Age 18 - 75 Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus ... (more)

    Comment?

  7. Kwang Dong Pharmaceutical Co., Ltd. (009290) - Pharmaceuticals &...Read the original story

    Mar 5, 2014 | PR-inside.com

    It manufactures and sales oriental herbal medicines and pharmaceutical products.

    Comment?

  8. Aurinia to Present at the 26th Annual ROTH ConferenceRead the original story

    Mar 4, 2014 | GlobeNewswire

    Aurinia Pharmaceuticals Inc. today announced that its President and CEO, Stephen Zaruby, will present an overview of the Company at the 26th Annual ROTH Conference on Monday, March 10 at 10:00 a.m. Pacific Time.

    Comment?

  9. Trichodysplasia spinulosaRead the original story

    Feb 28, 2014 | Kidney International

    Correspondence: Pankaj Jawa, Department of Nephrology, Einstein Medical Center, 5501 Old York Road, Philadelphia, Pennsylvania 19130, USA.

    Comment?

  10. Aurinia Announces US$52 Million Private PlacementRead the original story

    Feb 14, 2014 | Hispanic Business

    Aurinia intends to use the net proceeds from the Offering to advance the clinical and nonclinical development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis and for general corporate purposes.

    Comment?

  11. GlaxoSmithKline Finally Starts Much-Anticipated Phase 3 Study For Rare DiseaseRead the original story

    Feb 14, 2014 | BioSpace

    February 14, 2014 -- GlaxoSmithKline today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, in patients with Eosinophilic Granulomatosis with Polyangiitis .

    Comment?

  12. GSK announces start of Phase lll study for mepolizumab in patients...Read the original story

    Feb 14, 2014 | PressReleasePoint

    GlaxoSmithKline today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, in patients with Eosinophilic Granulomatosis with Polyangiitis .

    Comment?

  13. Late antibody-mediated rejection after ABO-incompatible kidney...Read the original story

    Feb 11, 2014 | BioMed Central

    The major challenge in ABO-incompatible transplantation is to minimize antibody-mediated rejection.

    Comment?

  14. Research and Markets: PharmaPoint: Atopic Dermatitis - Germany Drug...Read the original story

    Feb 10, 2014 | Business Wire

    Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

    Comment?

  15. Can we prevent donor-specific antibodies from developing after...Read the original story

    Jan 31, 2014 | Kidney International

    Correspondence: Lionel Rostaing, Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, TSA 50032, 31059 Toulouse, Cedex 9, France.

    Comment?

  16. Neither pre-transplant rituximab nor splenectomy affects de novo HLA...Read the original story

    Jan 31, 2014 | Kidney International

    Correspondence: Takaaki Kobayashi, Department of Transplant Immunology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.

    Comment?

  17. New Market Research Report: PharmaPoint: Atopic Dermatitis - Germany...Read the original story

    Jan 29, 2014 | SBWire

    Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

    Comment?

  18. PharmaPoint: Atopic Dermatitis - Germany Drug Forecast and Market...Read the original story

    Jan 23, 2014 | PR-inside.com

    By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

    Comment?

  19. Can a combined screening/treatment programme prevent premature...Read the original story

    Jan 21, 2014 | Trials Journal

    Renal transplantation is the best treatment for kidney failure, in terms of length and quality of life and cost-effectiveness.

    Comment?

  20. MarketResearchReports.com: Atopic Dermatitis - Germany Drug Forecast...Read the original story

    Jan 15, 2014 | SBWire

    Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

    Comment?